These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Role of mucosal mast cells in visceral hypersensitivity in a rat model of irritable bowel syndrome.
    Author: La JH, Kim TW, Sung TS, Kim HJ, Kim JY, Yang IS.
    Journal: J Vet Sci; 2004 Dec; 5(4):319-24. PubMed ID: 15613815.
    Abstract:
    The involvement of mucosal mast cells (MMC) in the pathophysiology of irritable bowel syndrome (IBS) is still controversial. We aimed to re-evaluate the role of MMC in visceral hypersensitivity associated with IBS using a rat IBS model that develops the IBS symptom after a subsidence of acetic acid-induced colitis. No significant difference in the number of MMC was observed between normal rat colon and IBS rat colon. (61.7 +/- 2.9/mm(2) in normal vs. 88.7 +/- 13.3/mm(2) in IBS, p > 0.29). However, the degranulation rate of MMC was significantly higher in IBS rat colon (49.5 +/- 2.4% in normal vs. 68.8 +/- 3.4% in IBS, p < 0.05). Pretreatment of a mast cell stabilizer, doxantrazole (5 mg/kg, i.p.), reduced the degranulation rate of MMC and significantly attenuated visceral hypersensitivity to rectal distension in IBS rat, whereas it had no effect on the visceral sensory responses in normal rat. These results suggest that, although the number of MMC is not significantly changed in IBS rat colon, the higher degranulation rate of MMC is responsible for visceral hypersensitivity in this model IBS.
    [Abstract] [Full Text] [Related] [New Search]